Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
Trial Parameters
Brief Summary
The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of mild cognitive impairment (MCI). * Clinical diagnosis of Alzheimer's Disease. * MCI and AD patients with hyperglycemia ( Fasting glucose \>=100 mg/dL). * MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance). * Must be able to swallow tablets. Exclusion Criteria: * Cancer patients. * Severe heart, lung, liver, and kidney diseases. * Severe disability or aphasia. * Malnutrition (body weight changes \> 5% within one month). * Using coenzyme Q10 supplements. * Warfarin therapy.